Acurx Pharma Q2 net loss widens to $3.4M; Phase 2b enrollment ongoing

Acurx Pharmaceuticals, Inc.

2023-Q2 EPS reported -$0.53

Net loss Q2 2023: $3.4M ($0.28/sh) vs $2.6M ($0.26/sh) in Q2 2022.
Cash unchanged at $9.1M as of June 30, 2023; no revenue reported.
Phase 2b trial for ibezapolstat in C. difficile: 28 sites enrolling; 5 patients needed for interim IDMC review.
R&D expenses rose to $1.7M (Q2 2023) from $0.9M (Q2 2022) driven by Phase 2b costs.
CARB-X declined grant for ACX375C pre-clinical candidate; encouraged re-application.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Acurx Pharmaceuticals, Inc. reported the second quarter ended June 30, 2023 results: net income a net loss of $3.4 million or $0.28 per diluted share, EPS $0.28 per diluted share.

Period: the second quarter ended June 30, 2023
Net income: a net loss of $3.4 million or $0.28 per diluted share
EPS: $0.28 per diluted share
Result: reported results

Exact text from the filing

The Company reported a net loss of $3.4 million or $0.28 per diluted share for the three months ended June 30, 2023, compared to a net loss of $2.6 million or $0.26 per diluted share for the three months ended June 30, 2022

View on SEC.gov

Browse all earnings releases →

Acurx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-090878

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.